Cu-64 DOTATATE PET could handle neuroendocrine tumors
PET imaging with copper-64 (Cu-64) DOTATATE could become a lower-radiation...Read more on AuntMinnie.comRelated Reading: RadioMedix, Curium file NDA for PET agent New class of radiotracers targets many cancer types FDA to fast track RadioMedix, Curium PET agent RadioMedix, ITM ink radiopharmaceutical generator deal Novel PET agent targets copper in prostate tumorsComments: 1/15/2020 8:18:43 AMNucMedPhysGuy Misleading use of the word "dose" here. Yes, injected activity is lower, but the patient absorbed dose is going to be much higher due to the 12 hour half life. "Lower radiation dose" typically implies absorbed or effective dose, not injected activity.
Publication date: Available online 1 April 2020Source: Journal of Molecular LiquidsAuthor(s): Xianting Xie, Lu Zhang, Wenjuan Zhang, Reza Tayebee, Atefe Hoseininasr, Hamid H. Vatanpour, Zeinab Behjati, Suying Li, Marjan Nasrabadi, Liuyi Liu
Publication date: Available online 1 April 2020Source: Carbohydrate PolymersAuthor(s): Chia-Hsiang Yen, Sheng-Tien Li, Nai-Chen Cheng, You-Ren Ji, Jyh-Horng Wang, Tai-Horng Young
Publication date: Available online 1 April 2020Source: Inorganica Chimica ActaAuthor(s): Sourav De, S.K. Ashok Kumar
Publication date: Available online 1 April 2020Source: European Polymer JournalAuthor(s): Himani Kalita, Manoj Patowary
Conclusion: CD26 is involved in the pathogenesis of colorectal diseases; sCD26 is diminished in CRC patients suggesting the potential utility of a sCD26 for diagnosis. PMID: 32223519 [PubMed - as supplied by publisher]
Publication date: Available online 2 April 2020Source: Preventive MedicineAuthor(s): Francesca Holme, Jose Jeronimo, Francisco Maldonado, Claudia Camel, Manuel Sandoval, Benito Martinez-Granera, Mirna Montenegro, Jacqueline Figueroa, Rose Slavkovsky, Kerry A. Thomson, Silvia de Sanjose, the Scale-Up project team
Publication date: Available online 1 April 2020Source: Preventive MedicineAuthor(s): Shelton J. Bartley, Vicki Benard, Eric Tai, Tanner Rockwell, Kristy Kenney, Lisa C. Richardson
Two University of Rochester physicians — one as an investigator and one as a patient — had major roles in a cutting-edge clinical trial using the body’s own immune cells to fight late-stage cancer. The striking results, showing that 93 percent of the study patients responded to the treatment, were reported in the April 2, 2020, iss ue of New England Journal of Medicine.
Publication date: Available online 2 April 2020Source: The American Journal of SurgeryAuthor(s): Zhi Ven Fong, David C. Chang, Chin Hur, Ginger Jin, Angela Tramontano, Naomi M. Sell, Andrew L. Warshaw, Carlos Fernandez del Castillo, Cristina R. Ferrone, Keith D. Lillemoe, Motaz Qadan
Conclusion: This study demonstrates the unequal manifestation of EOGC within the two ethnic groups of Han and Yi. However, familial clustering was infrequent. Further investigations are necessary to discover relevant risk factors apart from hereditary predisposition. PMID: 32231466 [PubMed - in process]